According to Kamada
's latest financial reports the company has $55.64 M in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | $55.64 M | 62.42% |
2022-12-31 | $34.25 M | 84.31% |
2021-12-31 | $18.58 M | -82.99% |
2020-12-31 | $0.10 B | 47.84% |
2019-12-31 | $73.9 M | 46.08% |
2018-12-31 | $50.59 M | 17.6% |
2017-12-31 | $43.01 M | 50.25% |
2016-12-31 | $28.63 M | 1.15% |
2015-12-31 | $28.3 M | -45.46% |
2014-12-31 | $51.89 M | -30.04% |
2013-12-31 | $74.17 M | 119.49% |
2012-12-31 | $33.79 M | -18.25% |
2011-12-31 | $41.33 M | -10.3% |
2010-12-31 | $46.08 M | 49.1% |
2009-12-31 | $30.9 M | 132.82% |
2008-12-31 | $13.27 M |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
Vertex Pharmaceuticals VRTX | $11.21 B | 20,061.93% | ๐บ๐ธ USA |
Compugen CGEN | $50.68 M | -8.91% | ๐ฎ๐ฑ Israel |